First presentation of atherosclerotic cardiovascular disease in previously healthy individuals: The multi-ethnic study of atherosclerosis.

T Cells, Triglycerides, and the Immune Roots of Residual Cardiovascular Risk.

Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD.

ASPC president's page: Preparing the next generation of leaders in preventive cardiology.

The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Scientific Statement from the Heart Failure Society of America and The American Society for Preventive Cardiology.

The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology.

Sex disparities in statin use following coronary computed tomography angiography.

Association of Plasma Lipoprotein(a) With Major Adverse Cardiovascular Events in MASLD With or Without Advanced Liver Fibrosis.

AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank.

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes.